WST 11-mediated VTP therapy

Phase 1Small molecule

WST 11-mediated VTP therapy is one of 4 small molecule programs targeting Cancer of the Esophagus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of the EsophagusActive, not recruiting

Cancer of the EsophagusPhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Cancer of the Esophagus

#DrugCompanyPhaseTrials

WST 11-mediated VTP therapy

MMemorial Sloan Kettering Cancer Center

Phase 1

1 2

Modified FOLFOX6

Amgen

Preclinical

1 3

Docetaxel/capecitabine

GGeorgia Center for Oncology Research & Education

Preclinical

1 4

Cisplatin/docetaxel

GGeorgetown University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cancer of the Esophagus1 trial

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03133650·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for WST 11-mediated VTP therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WST 11-mediated VTP therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WST 11-mediated VTP therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

WST 11-mediated VTP therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cancer of the Esophagus1 trial

References

Drug Info

Quick Facts

Related News